Chardan Capital Markets Reiterates Buy Rating on Dyne Therapeutics (DYN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
H.C. Wainwright Reiterates Buy Rating on Dyne Therapeutics (DYN)
March 17, 2025 9:39 AM EDTH.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $46.00 price target on Dyne Therapeutics (NASDAQ: DYN).
The analyst comments "Valuations and risks. Our price target of $46 is based on an equally weighted composite of: (a) $53/share, as a 25x multiple of taxed... More
